Biote corp.
About Biote. Founded in 2012, Biote has experience phenomenal growth over the last decade. The Biote state-of-the-art training facility hosts physicians, healthcare providers, and medical staff members monthly during the Biote Method learning and certification process. To date, more than 6,400 medical practitioners have successfully completed ...
Biote Holdings is merging with blank-cheque firm Haymaker Acquisition in a $737m (£556.8m) transaction to take it public, the companies have announced. Haymaker Acquisition stock rose 0.70% to $10.70 from $10 per share after the market open but fell to $9.91 per share by noon EDT (UTC-5). Haymaker Acquisition trades over the Nasdaq exchange ...In this case, outsourcing facilities, Carie Boyd’s Prescription Shop and AnazaoHealth Corporation, produced the pellets, but they were marketed by BioTe Medical, which was not registered with ...On May 26, 2022 (the “Closing Date”), the Business Combination with Holdings was consummated, resulting in Biote being organized in an “Up-C” structure, and HYAC as the registrant changed its name to “biote Corp. ” Biote’s headquarters are located at 1875 W. Walnut Hill Ln #100 Irving, Texas 75038.Biote Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 May. 09: CI Certain Restricted Stock Units of biote Corp. are subject to a Lock-Up Agreement Ending on 6-APR-2023. Apr. 05: CI Certain Stock Options of biote Corp. are subject to a Lock-Up Agreement Ending on 6-APR-2023.
Nov 8, 2023 · Biote Corp. (BTMD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.08. This compares to loss of $0.09 per share a year ago. These figures are adjusted ... IRVING, Texas -- (BUSINESS WIRE)--Nov. 7, 2023-- Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for the third quarter ended September 30, 2023 .
Biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build, and implement a program designed to optimize hormone levels. The Company's Biote Method is a comprehensive, end-to-end practice …Exhibit 99.1 . Biote Appoints Debby Morris to Board of Directors . IRVING, TX – November 7, 2022 – biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Debby Morris to Biote’s Board of Directors.
IRVING, Texas--(BUSINESS WIRE)--Aug. 15, 2022-- Biote today issued a correction to operating loss and net income for the three and six month periods ended June 30, 2022 in the press release titled “Biote Reports Second Quarter 2022 Financial Results,” issued on August 9, 2022.The other financial results reported in the original press …As previously disclosed, on May 9, 2023, biote Corp. (the “ Company ”), commenced (i) its offer to each holder of its outstanding warrants, each whole warrant exercisable for one share of Class A Common Stock, par value $0.0001 per share (“ Common Stock ”), of the Company, at an exercise price of $11.50 per share (the “ Warrants ...IRVING, Texas--(BUSINESS WIRE)--May 9, 2023-- Biote (NASDAQ: BTMD) (the “Company,” “we” or “us”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that it has commenced an exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its (i) 8,397,624 outstanding ...Biote Corp. Reconciliation of Adjusted EBITDA to Net (Loss) Income (In Thousands) (Unaudited) Three Months Ended Nine Months Ended. September 30, September 30, 2022 2021 2022 2021. Net income (loss) $ (6,346 ) $ 8,537 $ 43,345 $ 27,139 Interest expense 1,756 384 2,909 1,301 Income tax expense (benefit) 234
View the latest Biote Corp. (BTMD) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Following the transaction, the combined company was renamed biote Corp., and its Class A common stock and warrants will begin trading on the Nasdaq Stock Exchange under the symbols “BTMD” and ...
As previously disclosed, on May 9, 2023, biote Corp. (the “Company”), commenced (i) its offer to each holder of its outstanding warrants, each whole warrant exercisable for one share of Class A Common Stock, par value $0.0001 per share (“Common Stock”), of the Company, at an exercise price of $11.50 per share (the “Warrants”), the opportunity to receive 0.23 shares of Common Stock ...TO BE HELD ON MAY 24, 2022. On May 5, 2022, Haymaker Acquisition Corp. III (“Haymaker” or the “Company”) filed a Definitive Proxy Statement on Schedule 14A (the “Proxy Statement”) with the Securities and Exchange Commission (“SEC”) in connection with the Business Combination Agreement, dated as of December 13, 2021 (as amended ...Dec 13, 2021 · Biote derives revenues by contractually sharing in the profit generated by Biote-certified practitioners and through the sale of its Biote-branded nutraceutical products. Biote-certified practitioners deliver personalized hormone replacement therapy to relieve the symptoms of hormonal imbalance, which affects approximately 200 million Americans. Get the latest biote Corp (BTMD) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Feb 9, 2023 · IRVING, Texas--(BUSINESS WIRE)--Feb. 9, 2023-- Biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide fourth quarter and full year financial results on Tuesday, March 28, 2023, after the close of the market.
Biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote …Biote Corp. (BTMD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.08. This compares to loss of $0.09 per share a year ago. These figures are adjusted ...Terry Weber. Biote Purdue University. Irving, Texas, United States. 2K followers 500+ connections.Biote derives revenues by contractually sharing in the profit generated by Biote-certified practitioners and through the sale of its Biote-branded nutraceutical products. Biote-certified practitioners deliver personalized hormone replacement therapy to relieve the symptoms of hormonal imbalance, which affects approximately 200 million Americans.Biote Corp. Consolidated Balance Sheets (In Thousands) (Unaudited) September 30, December 31, 2023 2022 Assets: Current assets: Cash and cash equivalents $ 65,575 $ 79,231 Short-term investment ...
IRVING, TX, August 25, 2022 — biote Corp. (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that The Nasdaq Stock Market LLC (“Nasdaq”) has approved its application for the relisting of the Company’s common stock and warrants on The ...IRVING, Texas--(BUSINESS WIRE)--May 9, 2023-- Biote (NASDAQ: BTMD) (the “Company,” “we” or “us”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that it has commenced an exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its (i) 8,397,624 outstanding ...
May 30, 2023 · Ms. Puncochar to Drive Execution of Biote’s Strategic Sales and Marketing Initiatives. IRVING, Texas--(BUSINESS WIRE)--May 30, 2023-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Mary J. Puncochar as Chief Commercial Officer. IRVING, TX, December 13, 2021 — BioTE Holdings, LLC, (Biote), a high-growth, differentiated medical practice-building business within the hormone optimization space (“Biote”), and Haymaker Acquisition Corp. III (Nasdaq: HYAC) (“Haymaker”), a special purpose acquisition company, today announced that they have entered into a definitive ...Terry Weber. Biote Purdue University. Irving, Texas, United States. 2K followers 500+ connections.Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.2023 Third Quarter Financial Review. Revenue for the third quarter of 2023 was $45.6 million, an increase of 8.5% from $42.0 million for the third quarter of 2022. The increase in revenue was driven by procedure revenue growth of 7.4% and dietary supplement revenue growth of 5.1%. As expected, third quarter dietary supplement revenue growth ...The Investor Relations website contains information about biote Corp's business for stockholders, potential investors, and financial analysts. Biote Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 May. 09: CI Certain Restricted Stock Units of biote Corp. are subject to a Lock-Up Agreement Ending on 6-APR-2023. Apr. 05: CI Certain Stock Options of biote Corp. are subject to a Lock-Up Agreement Ending on 6-APR-2023.
Nov 7, 2022 · IRVING, Texas -- (BUSINESS WIRE)--Nov. 7, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Debby Morris to Biote’s Board of Directors. Ms. Morris brings more than three decades of ...
Biote is a hormone optimization company that has translated over 80 years of scientific insight into clinically-validated medical approaches that identify ...
Jun 8, 2023 · As previously disclosed, on May 9, 2023, biote Corp. (the “ Company ”), commenced (i) its offer to each holder of its outstanding warrants, each whole warrant exercisable for one share of Class A Common Stock, par value $0.0001 per share (“ Common Stock ”), of the Company, at an exercise price of $11.50 per share (the “ Warrants ”), the opportunity to receive 0.23 shares of Common ... Jan 5, 2023 · IRVING, Texas--(BUSINESS WIRE)--Jan. 5, 2023-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the pricing of an underwritten public offering of its Class A common stock by certain of its stockholders at a price to the public of $3.00 per share. Item 4.02. Non-Reliance on Previously Issued Financial Statements or a Related. Audit Report or Completed Interim Review. (a) On March 24, 2023, the audit committee of the board of directors (the "Audit Committee") of biote Corp. (the "Company"), based on the recommendation of, and after consultation with, the Company's …IRVING, Texas -- (BUSINESS WIRE)--Nov. 7, 2023-- Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of …Aug 9, 2022 · On June 5, 2023, biote Corp. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Roth Capital Partners, LLC, as the underwriter (the “Underwriter”), and a selling stockholder (the “Selling Stockholder”), in connection with the offering and sale (the “Offering”) by the Selling Stockholder of 5,217,392 shares (the “shares”) of Class ... Achieved Full Year 2022 Record Revenue and Adjusted EBITDA for Full Year 2022 Expect 2023 Revenue of $190-200 million and Adjusted EBITDA of $56-60 million Significantly Increased Trading Liquidity...A certain stockholder of biote Corp., a Delaware corporation (the “Company”) named in Schedule II attached hereto (the “Selling Stockholder”), propose, subject to the terms and conditions herein, to sell 5,217,392 shares (the “Firm Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”).Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. WHO IS BIOTE? Biote is a leading innovator in precision and preventive medicine. For patients, it is a way for them to take control of their health through hormone optimization. For providers, it’s a way to learn how to identify and address the earliest indicators of aging.*
Cooley LLP served as legal advisor to Biote. DLA Piper LLP (US) served as legal advisor to Haymaker Acquisition Corp. III. About Biote . Biote is a woman-led company operating a high growth, differentiated medical practice-building business within the hormone optimization space. Biote trains practitioners how to identify and treat early indicators of …Conference Call: Terry Weber, Chief Executive Officer, and the Company’s management will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET on Wednesday, March 29, 2023. To access the conference call by telephone, please dial (866) 524-3160 (U.S toll-free) or (412) 317-6760 …Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for the third quarter ended September 30, 2023.. Third Quarter 2023 Financial Highlights (All financial result comparisons made are against the prior year period) …Instagram:https://instagram. charge point for teslaamerican pipelinewhat time is the iphone 15 pre orderbean stocks biote Corp. 1875 West Walnut Hill Lane Suite 100 Irving, TX 75038 United States 844 604 1246 https://biote.com Sector(s) : Healthcare Industry : Medical Care Facilities Full Time Employees : 186 vanguard target 2070high income.skills 2023 IRVING, TX, December 13, 2021 — BioTE Holdings, LLC, (Biote), a high-growth, differentiated medical practice-building business within the hormone optimization space (“Biote”), and Haymaker Acquisition Corp. III (Nasdaq: HYAC) (“Haymaker”), a special purpose acquisition company, today announced that they have entered into a definitive …IRVING, Texas--(BUSINESS WIRE)--Jan. 9, 2023-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the closing of its previously announced underwritten public offering of 8,500,000 shares of its Class A common stock … dividend payout date Biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build, and implement a program designed to optimize hormone levels. The Company's Biote Method is a comprehensive, end-to-end practice …Jun 8, 2023 · Corporate Profile. Biote operates a high growth, differentiated medical practice-building business within the hormone optimization space. Similar to a franchise model, Biote provides the necessary components to enable practitioners to establish, build, and successfully operate a hormone optimization center to treat patients appropriate for therapy.